Literature DB >> 22764258

Increased PK11195 PET binding in the cortex of patients with MS correlates with disability.

Marios Politis1, Paolo Giannetti, Paul Su, Federico Turkheimer, Shiva Keihaninejad, Kit Wu, Adam Waldman, Omar Malik, Paul M Matthews, Richard Reynolds, Richard Nicholas, Paola Piccini.   

Abstract

OBJECTIVE: Activated microglia are thought to play a major role in cortical gray matter (GM) demyelination in multiple sclerosis (MS). Our objective was to evaluate microglial activation in cortical GM of patients with MS in vivo and to explore its relationship to measures of disability.
METHODS: Using PET and optimized modeling and segmentation procedures, we investigated cortical (11)C-PK11195 (PK11195) binding in patients with relapsing-remitting MS (RRMS), patients with secondary progressive MS (SPMS), and healthy controls. Disability was assessed with the Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Impact Scale (MSIS-29).
RESULTS: Patients with MS showed increased cortical GM PK11195 binding relative to controls, which was multifocal and highest in the postcentral, middle frontal, anterior orbital, fusiform, and parahippocampal gyri. Patients with SPMS also showed additional increases in precentral, superior parietal, lingual and anterior superior, medial and inferior temporal gyri. Total cortical GM PK11195 binding correlated with EDSS scores, with a stronger correlation for the subgroup of patients with SPMS. In patients with SPMS, PK11195 binding also correlated with MSIS-29 scores. No correlation with disability measures was seen for PK11195 binding in white matter. Higher EDSS scores correlated with higher levels of GM PK11195 binding in the postcentral gyrus for patients with RRMS and in precentral gyrus for those with SPMS.
CONCLUSIONS: Microglial activation in cortical GM of patients with MS can be assessed in vivo. The distribution is not uniform and shows a relationship to clinical disability. We speculate that the increased PK11195 binding corresponds to enhanced microglial activation described in postmortem SPMS cortical GM.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22764258      PMCID: PMC3413767          DOI: 10.1212/WNL.0b013e3182635645

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  39 in total

Review 1.  Microglial functions and proteases.

Authors:  Hiroshi Nakanishi
Journal:  Mol Neurobiol       Date:  2003-04       Impact factor: 5.590

2.  ATP mediates rapid microglial response to local brain injury in vivo.

Authors:  Dimitrios Davalos; Jaime Grutzendler; Guang Yang; Jiyun V Kim; Yi Zuo; Steffen Jung; Dan R Littman; Michael L Dustin; Wen-Biao Gan
Journal:  Nat Neurosci       Date:  2005-05-15       Impact factor: 24.884

3.  Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study.

Authors:  J Versijpt; J C Debruyne; K J Van Laere; F De Vos; J Keppens; K Strijckmans; E Achten; G Slegers; R A Dierckx; J Korf; J L De Reuck
Journal:  Mult Scler       Date:  2005-04       Impact factor: 6.312

4.  NEMA NU 2-2001 performance measurements of an LYSO-based PET/CT system in 2D and 3D acquisition modes.

Authors:  Brad J Kemp; Chang Kim; John J Williams; Alexander Ganin; Val J Lowe
Journal:  J Nucl Med       Date:  2006-12       Impact factor: 10.057

5.  Cortical demyelination and diffuse white matter injury in multiple sclerosis.

Authors:  Alexandra Kutzelnigg; Claudia F Lucchinetti; Christine Stadelmann; Wolfgang Brück; Helmut Rauschka; Markus Bergmann; Manfred Schmidbauer; Joseph E Parisi; Hans Lassmann
Journal:  Brain       Date:  2005-10-17       Impact factor: 13.501

6.  High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosis.

Authors:  Klaus Schmierer; Harold G Parkes; Po-Wah So; Shu F An; Sebastian Brandner; Roger J Ordidge; Tarek A Yousry; David H Miller
Journal:  Brain       Date:  2010-01-31       Impact factor: 13.501

7.  Multiple sclerosis and Alzheimer's disease.

Authors:  Assunta Dal Bianco; Monika Bradl; Josa Frischer; Alexandra Kutzelnigg; Kurt Jellinger; Hans Lassmann
Journal:  Ann Neurol       Date:  2008-02       Impact factor: 10.422

8.  PET visualization of microglia in multiple sclerosis patients using [11C]PK11195.

Authors:  J C Debruyne; J Versijpt; K J Van Laere; F De Vos; J Keppens; K Strijckmans; E Achten; G Slegers; R A Dierckx; J Korf; J L De Reuck
Journal:  Eur J Neurol       Date:  2003-05       Impact factor: 6.089

9.  Novel reference region model reveals increased microglial and reduced vascular binding of 11C-(R)-PK11195 in patients with Alzheimer's disease.

Authors:  Giampaolo Tomasi; Paul Edison; Alessandra Bertoldo; Federico Roncaroli; Poonam Singh; Alexander Gerhard; Claudio Cobelli; David J Brooks; Federico E Turkheimer
Journal:  J Nucl Med       Date:  2008-07-16       Impact factor: 10.057

10.  Chronic glial activation, neurodegeneration, and APP immunoreactive deposits following acute administration of double-stranded RNA.

Authors:  Lisa M Melton; Alexander B Keith; Sue Davis; Arthur E Oakley; James A Edwardson; Christopher M Morris
Journal:  Glia       Date:  2003-10       Impact factor: 7.452

View more
  72 in total

Review 1.  The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials.

Authors:  Kedar R Mahajan; Daniel Ontaneda
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 2.  Positron emission tomography imaging in neurological disorders.

Authors:  Marios Politis; Paola Piccini
Journal:  J Neurol       Date:  2012-09       Impact factor: 4.849

3.  Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions.

Authors:  Ulrike W Kaunzner; Yeona Kang; Shun Zhang; Eric Morris; Yihao Yao; Sneha Pandya; Sandra M Hurtado Rua; Calvin Park; Kelly M Gillen; Thanh D Nguyen; Yi Wang; David Pitt; Susan A Gauthier
Journal:  Brain       Date:  2019-01-01       Impact factor: 13.501

Review 4.  Advances in CNS Imaging Agents: Focus on PET and SPECT Tracers in Experimental and Clinical Use.

Authors:  Noble George; Emily G Gean; Ayon Nandi; Boris Frolov; Eram Zaidi; Ho Lee; James R Brašić; Dean F Wong
Journal:  CNS Drugs       Date:  2015-04       Impact factor: 5.749

5.  Validation of an automatic reference region extraction for the quantification of [18F]DPA-714 in dynamic brain PET studies.

Authors:  Daniel García-Lorenzo; Sonia Lavisse; Claire Leroy; Catriona Wimberley; Benedetta Bodini; Philippe Remy; Mattia Veronese; Federico Turkheimer; Bruno Stankoff; Michel Bottlaender
Journal:  J Cereb Blood Flow Metab       Date:  2017-02-09       Impact factor: 6.200

Review 6.  Neuroinflammatory imaging biomarkers: relevance to multiple sclerosis and its therapy.

Authors:  Thomas Tourdias; Vincent Dousset
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

Review 7.  Can we switch microglia's phenotype to foster neuroprotection? Focus on multiple sclerosis.

Authors:  Debora Giunti; Benedetta Parodi; Christian Cordano; Antonio Uccelli; Nicole Kerlero de Rosbo
Journal:  Immunology       Date:  2014-03       Impact factor: 7.397

Review 8.  Grey matter damage in multiple sclerosis: a pathology perspective.

Authors:  Roel Klaver; Helga E De Vries; Geert J Schenk; Jeroen J G Geurts
Journal:  Prion       Date:  2013-01-01       Impact factor: 3.931

Review 9.  Imaging as an Outcome Measure in Multiple Sclerosis.

Authors:  Daniel Ontaneda; Robert J Fox
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

10.  Changes and variability of proton density and T1 relaxation times in early multiple sclerosis: MRI markers of neuronal damage in the cerebral cortex.

Authors:  René-Maxime Gracien; Sarah C Reitz; Stephanie Michelle Hof; Vinzenz Fleischer; Hilga Zimmermann; Amgad Droby; Helmuth Steinmetz; Frauke Zipp; Ralf Deichmann; Johannes C Klein
Journal:  Eur Radiol       Date:  2015-10-22       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.